Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
Hematol Oncol. 2010 Jun;28(2):62-7. doi: 10.1002/hon.932.
Richter's syndrome (RS) represents the transformation of chronic lymphocytic leukaemia (CLL) to aggressive lymphoma and is mostly represented by diffuse large B-cell lymphoma (DLBCL), with a post-germinal centre (GC) phenotype, clonally related to the pre-existing CLL. RS has a very poor prognosis and its pathogenetic mechanisms are poorly understood. In order to gain additional hints in RS pathogenesis, we performed a genome-wide DNA profiling study of 13 RS phases and eight matched CLL phases using the Affymetrix Human Mapping 250K NspI SNP arrays. Individual genomic profiles were heterogeneous, with no individual lesions occurring in more than half of the cases. However, several observations suggest that MYC pathway might be involved in RS. The 13q13.3-qter region containing MIRHG1 (MIR-17-92), a cluster of microRNA interacting with c-MYC, was acquired at the time of transformation. The 13q gain was coupled with the gain of c-MYC and loss of TP53. Translocation of c-MYC was acquired at transformation in a fraction of cases and this event appeared mutually exclusive with gain of MIRHG1. MYCN, a c-MYC homologue, was also recurrently gained. By comparing RS with 48 de novo DLBCL, RS presented a significantly lower prevalence of deletions affecting the PRDM1 and TNFAIP3, genes on 6q, known to be associated with a post-GC phenotype. In conclusion, the genomic profile of RS seems to differ from what observed in de novo DLBCL and in other transformed DLBCL. Genomic lesions occurring in RS are heterogeneous suggesting the existence of different RS subsets, possibly due to different transforming mechanisms. A deregulation of MYC pathway might represent one of the main transformation events in the pathogenesis of a subset of RS clonally related to the previous CLL.
里希特氏综合征 (RS) 代表慢性淋巴细胞白血病 (CLL) 向侵袭性淋巴瘤的转化,主要表现为弥漫性大 B 细胞淋巴瘤 (DLBCL),具有生发中心后 (GC) 表型,与先前存在的 CLL 克隆相关。RS 预后极差,其发病机制尚不清楚。为了在 RS 发病机制中获得更多线索,我们使用 Affymetrix Human Mapping 250K NspI SNP 阵列对 13 个 RS 期和 8 个匹配的 CLL 期进行了全基因组 DNA 谱分析研究。个体基因组谱是异质性的,没有个体病变发生在一半以上的病例中。然而,有几个观察结果表明 MYC 途径可能参与了 RS。包含 MIRHG1(MIR-17-92)的 13q13.3-qter 区域,是一个与 c-MYC 相互作用的 microRNA 簇,在转化时被获得。13q 增益与 c-MYC 增益和 TP53 缺失相关。在部分病例中,c-MYC 的易位在转化时获得,并且该事件与 MIRHG1 的获得是相互排斥的。c-MYC 的同源物 MYCN 也经常获得。通过将 RS 与 48 例新发 DLBCL 进行比较,RS 中影响 6q 上 PRDM1 和 TNFAIP3 的缺失的发生率明显较低,这些基因与 GC 后表型有关。总之,RS 的基因组谱似乎与新发 DLBCL 和其他转化的 DLBCL 不同。发生在 RS 中的基因组病变是异质性的,这表明存在不同的 RS 亚群,可能是由于不同的转化机制。MYC 途径的失调可能代表与先前 CLL 克隆相关的 RS 亚群发病机制中的主要转化事件之一。